Cargando…

Expression of anti-apoptotic protein survivin in human endometrial carcinoma: Clinical and pathological associations as a separate factor and in combination with concomitant PTEN and p53 expression

Endometrial carcinoma is one of the most common types of gynecological cancer. A total of 99 cases of primary endometrial carcinoma were investigated for survivin expression by immunohistochemistry. Furthermore, the association between concomitant survivin, PTEN and p53 expression, and clinicopathol...

Descripción completa

Detalles Bibliográficos
Autores principales: Stavropoulos, Aggelis, Varras, Michail, Vasilakaki, Thivi, Varra, Viktoria-Konstantina, Varra, Fani-Niki, Tsavari, Aikaterini, Nonni, Aphrodite, Kavantzas, Nikolaos, Lazaris, Andreas C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377108/
https://www.ncbi.nlm.nih.gov/pubmed/32724342
http://dx.doi.org/10.3892/ol.2020.11690
_version_ 1783562159722070016
author Stavropoulos, Aggelis
Varras, Michail
Vasilakaki, Thivi
Varra, Viktoria-Konstantina
Varra, Fani-Niki
Tsavari, Aikaterini
Nonni, Aphrodite
Kavantzas, Nikolaos
Lazaris, Andreas C.
author_facet Stavropoulos, Aggelis
Varras, Michail
Vasilakaki, Thivi
Varra, Viktoria-Konstantina
Varra, Fani-Niki
Tsavari, Aikaterini
Nonni, Aphrodite
Kavantzas, Nikolaos
Lazaris, Andreas C.
author_sort Stavropoulos, Aggelis
collection PubMed
description Endometrial carcinoma is one of the most common types of gynecological cancer. A total of 99 cases of primary endometrial carcinoma were investigated for survivin expression by immunohistochemistry. Furthermore, the association between concomitant survivin, PTEN and p53 expression, and clinicopathological parameters was examined. Immunopositivity for survivin was identified in 88% of cases. Concomitant survivin, PTEN and p53 expression (staining scores and intensity) was observed in 60% of endometrial adenocarcinomas. A significant association was identified between the sum of staining intensity and scores of survivin immunopositive cells, and patient age (P=0.028), histological grade (P<0.001), clinical stage (P=0.018) and fallopian tube and/or ovarian invasion (P=0.039). A negative tendency for correlation was observed between surivin and PTEN immunostaining scores (P=0.062; ρ=−0.238). Specimens with high scores of survivin expression tended to show decreased scores of PTEN immunostaining, and vice versa. However, in circumstances with an increased co-expression of survivin and PTEN, a statistically significant association with histological types was observed (P=0.020). A statistically significant positive correlation was identified between survivin and p53 sum co-expression (P=0.008; ρ=0.300). Furthermore, a significant association was identified between survivin and p53 concomitant sum expression and age of patients (P=0.001), histological type (P=0.020), clinical stage (P=0.037), histological differentiation (P=0.001) and presence of fallopian tube and/or ovarian invasion (P=0.026). The present findings suggested that survivin may be an indicator of unfavorable outcome in older patients with endometrial carcinoma, in specific circumstances that are dependent on different concomitant genetic alterations and different combinations of molecular signaling pathways. Increased expression levels of survivin and PTEN may serve a role in the development of more aggressive endometrial carcinoma during their interaction. In addition, protein expression levels of survivin and p53 are positively correlated and may share a common molecular pathway to promote endometrial carcinogenesis. These findings provided evidence that survivin and p53 combined may be useful markers for the prediction of tumor behavior and prognosis.
format Online
Article
Text
id pubmed-7377108
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-73771082020-07-27 Expression of anti-apoptotic protein survivin in human endometrial carcinoma: Clinical and pathological associations as a separate factor and in combination with concomitant PTEN and p53 expression Stavropoulos, Aggelis Varras, Michail Vasilakaki, Thivi Varra, Viktoria-Konstantina Varra, Fani-Niki Tsavari, Aikaterini Nonni, Aphrodite Kavantzas, Nikolaos Lazaris, Andreas C. Oncol Lett Articles Endometrial carcinoma is one of the most common types of gynecological cancer. A total of 99 cases of primary endometrial carcinoma were investigated for survivin expression by immunohistochemistry. Furthermore, the association between concomitant survivin, PTEN and p53 expression, and clinicopathological parameters was examined. Immunopositivity for survivin was identified in 88% of cases. Concomitant survivin, PTEN and p53 expression (staining scores and intensity) was observed in 60% of endometrial adenocarcinomas. A significant association was identified between the sum of staining intensity and scores of survivin immunopositive cells, and patient age (P=0.028), histological grade (P<0.001), clinical stage (P=0.018) and fallopian tube and/or ovarian invasion (P=0.039). A negative tendency for correlation was observed between surivin and PTEN immunostaining scores (P=0.062; ρ=−0.238). Specimens with high scores of survivin expression tended to show decreased scores of PTEN immunostaining, and vice versa. However, in circumstances with an increased co-expression of survivin and PTEN, a statistically significant association with histological types was observed (P=0.020). A statistically significant positive correlation was identified between survivin and p53 sum co-expression (P=0.008; ρ=0.300). Furthermore, a significant association was identified between survivin and p53 concomitant sum expression and age of patients (P=0.001), histological type (P=0.020), clinical stage (P=0.037), histological differentiation (P=0.001) and presence of fallopian tube and/or ovarian invasion (P=0.026). The present findings suggested that survivin may be an indicator of unfavorable outcome in older patients with endometrial carcinoma, in specific circumstances that are dependent on different concomitant genetic alterations and different combinations of molecular signaling pathways. Increased expression levels of survivin and PTEN may serve a role in the development of more aggressive endometrial carcinoma during their interaction. In addition, protein expression levels of survivin and p53 are positively correlated and may share a common molecular pathway to promote endometrial carcinogenesis. These findings provided evidence that survivin and p53 combined may be useful markers for the prediction of tumor behavior and prognosis. D.A. Spandidos 2020-08 2020-05-30 /pmc/articles/PMC7377108/ /pubmed/32724342 http://dx.doi.org/10.3892/ol.2020.11690 Text en Copyright: © Stavropoulos et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Stavropoulos, Aggelis
Varras, Michail
Vasilakaki, Thivi
Varra, Viktoria-Konstantina
Varra, Fani-Niki
Tsavari, Aikaterini
Nonni, Aphrodite
Kavantzas, Nikolaos
Lazaris, Andreas C.
Expression of anti-apoptotic protein survivin in human endometrial carcinoma: Clinical and pathological associations as a separate factor and in combination with concomitant PTEN and p53 expression
title Expression of anti-apoptotic protein survivin in human endometrial carcinoma: Clinical and pathological associations as a separate factor and in combination with concomitant PTEN and p53 expression
title_full Expression of anti-apoptotic protein survivin in human endometrial carcinoma: Clinical and pathological associations as a separate factor and in combination with concomitant PTEN and p53 expression
title_fullStr Expression of anti-apoptotic protein survivin in human endometrial carcinoma: Clinical and pathological associations as a separate factor and in combination with concomitant PTEN and p53 expression
title_full_unstemmed Expression of anti-apoptotic protein survivin in human endometrial carcinoma: Clinical and pathological associations as a separate factor and in combination with concomitant PTEN and p53 expression
title_short Expression of anti-apoptotic protein survivin in human endometrial carcinoma: Clinical and pathological associations as a separate factor and in combination with concomitant PTEN and p53 expression
title_sort expression of anti-apoptotic protein survivin in human endometrial carcinoma: clinical and pathological associations as a separate factor and in combination with concomitant pten and p53 expression
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377108/
https://www.ncbi.nlm.nih.gov/pubmed/32724342
http://dx.doi.org/10.3892/ol.2020.11690
work_keys_str_mv AT stavropoulosaggelis expressionofantiapoptoticproteinsurvivininhumanendometrialcarcinomaclinicalandpathologicalassociationsasaseparatefactorandincombinationwithconcomitantptenandp53expression
AT varrasmichail expressionofantiapoptoticproteinsurvivininhumanendometrialcarcinomaclinicalandpathologicalassociationsasaseparatefactorandincombinationwithconcomitantptenandp53expression
AT vasilakakithivi expressionofantiapoptoticproteinsurvivininhumanendometrialcarcinomaclinicalandpathologicalassociationsasaseparatefactorandincombinationwithconcomitantptenandp53expression
AT varraviktoriakonstantina expressionofantiapoptoticproteinsurvivininhumanendometrialcarcinomaclinicalandpathologicalassociationsasaseparatefactorandincombinationwithconcomitantptenandp53expression
AT varrafaniniki expressionofantiapoptoticproteinsurvivininhumanendometrialcarcinomaclinicalandpathologicalassociationsasaseparatefactorandincombinationwithconcomitantptenandp53expression
AT tsavariaikaterini expressionofantiapoptoticproteinsurvivininhumanendometrialcarcinomaclinicalandpathologicalassociationsasaseparatefactorandincombinationwithconcomitantptenandp53expression
AT nonniaphrodite expressionofantiapoptoticproteinsurvivininhumanendometrialcarcinomaclinicalandpathologicalassociationsasaseparatefactorandincombinationwithconcomitantptenandp53expression
AT kavantzasnikolaos expressionofantiapoptoticproteinsurvivininhumanendometrialcarcinomaclinicalandpathologicalassociationsasaseparatefactorandincombinationwithconcomitantptenandp53expression
AT lazarisandreasc expressionofantiapoptoticproteinsurvivininhumanendometrialcarcinomaclinicalandpathologicalassociationsasaseparatefactorandincombinationwithconcomitantptenandp53expression